New combo therapy aims to shrink head and neck tumors before surgery
NCT ID NCT07371234
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing whether combining low-dose radiotherapy with the immunotherapy drug Toripalimab before surgery can improve outcomes for people with advanced head and neck squamous cell carcinoma. About 22 participants will receive two cycles of the combination, then undergo surgery. The main goal is to see how many patients have a major reduction in tumor cells after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Toripalimab (an anti-PD-1 immunotherapy drug) and low-dose radiotherapy
What this could lead to
If successful, this combination could shrink tumors before surgery, potentially improving survival and reducing recurrence for people with advanced head and neck cancer.
What could go wrong
This is a small, early-phase trial with only 22 participants, so results may not apply to everyone. The treatment may cause side effects from immunotherapy or radiation, and it's not yet proven to be better than standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Fifth Affiliated Hospital,Sun Yat-sen University
RECRUITINGGuangdong, China